At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
Bayer is a global enterprise with core competencies in the life science fields of ...
Bayer is a global enterprise with core competen...
Flexion Therapeutics is a biopharmaceutical company focused on the development and...
Flexion Therapeutics is a biopharmaceutical com...
Level Therapy is a platform that provides treatment tools and video access to lice...
Level Therapy is a platform that provides treat...
NeurMedix, Inc., is a clinical-stage biotechnology company that engages in develop...
NeurMedix, Inc., is a clinical-stage biotechnol...
Join the National Investor Network and get the latest information with your interests in mind.